NextCell Pharma AB (STO:NXTCL)

Market Cap	125.87M
Revenue (ttm)	10.24M
Net Income (ttm)	-39.76M
Shares Out	111.39M
EPS (ttm)	-0.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	192,459
Average Volume	175,423
Open	1.110
Previous Close	1.130
Day's Range	1.110 - 1.146
52-Week Range	0.690 - 3.840
Beta	0.18
RSI	44.20
Earnings Date	Oct 23, 2025

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NXTCL

Financial Performance

In 2024, NextCell Pharma AB's revenue was 11.28 million, a decrease of -19.18% compared to the previous year's 13.96 million. Losses were -41.96 million, 5.40% more than in 2023.